Oncopeptides
1.44 SEK
+3.52 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+3.52 %
-6.98 %
-58.26 %
-70.03 %
-72.31 %
-22.92 %
-81.11 %
-98.44 %
-95.01 %
Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.
Read moreMarket cap
569.21M SEK
Turnover
6.64M SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13/5
2026
Interim report Q1'26
21/5
2026
General meeting '26
27/8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Annual General Meeting in Oncopeptides
Oncopeptides, Audiocast, Q1'26
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
